Nasdaq Stockholm

EQL Pharma AB

ISIN SE0005497732Filings at the FI

At a glance

Most recent filing on August 19, 2026 — an open-market purchase by Allan Sylvest Aasberg on Aug 14, 2026.

We hold 100 visible filings, going back to September 22, 2017.

Filings we could not classify with confidence are set aside for review, so they are in none of these counts.

Insider trades

What is a MAR filing?

5 of 100 shown

This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings at this company, out of 100. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are the price history with every buy marked, the price change beside each line, and any moments with several buyers or buying streaks. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Allan Sylvest Aasberg Chief financial officer
527,200 SEKOpen-market buy
TradedAug 14, 2026FiledAug 19, 2026
Axel Schörling Chief executive officer
1,234,586 SEKOpen-market sale
TradedMar 27, 2026FiledMar 27, 2026
Magnus Erreth Other member of the administrative, management or supervisory body
57,700 SEKOpen-market buy
TradedDec 30, 2025FiledDec 30, 2025
Martin Kristofferson Other member of the administrative, management or supervisory body
1,004,891 SEKOpen-market buy
TradedDec 23, 2025FiledDec 23, 2025
Magnus Erreth Other member of the administrative, management or supervisory body
67,800 SEKOpen-market buy
TradedSep 23, 2025FiledSep 26, 2025